DETAILS, FICTION AND PONSEGROMAB

These trials showed clinically considerable pharmacokinetic interactions [seven] characterised by a lower during the clearance in the anticancer drug and for this reason increased exposure. The interpretation of subsequent phase II and III clinical trials was complicated because it was impossible to administer exactly the same dose of chemotherapy